Clinical Trials

Gene Therapy Clinical Trials

We have created a page with information on gene therapy clinical trials. Please visit our new page for more information on gene therapy and to see the current trials.


We want to empower you and anyone else affected by Gaucher disease by ensuring that you have adequate information in a format that is easily accessible.

We are aware of the challenges that can surround clinical trials for our patients. Our goal is to promote informed decision-making: this way, you always fully comprehend what is going on every step of the way.

You can find information regarding current trials on ClinicalTrials.gov including clinical sites, inclusion criteria, protocols etc. For your own convenience, trial numbers are listed below alongside the relevant company name(s), simply input these numbers in the search bar to learn more about each respective trial.

Company websites can be accessed simply by clicking the company name, and a summary of current Clinical Trials is shown below against each pharmaceutical company.

If you have any further queries regarding clinical trials please don’t hesitate to get in touch.


Current Substrate Reduction Therapy studies in Gaucher disease Type 1 and Type 3

Sanofi Genzyme are currently in clinical trials with an SRT called Venglustat for type 3 Gaucher disease. Venglustat is being investigated as a potential oral substrate reduction therapy for GD3. Preclinical studies indicate the novel oral treatment is a glucosylceramide synthase inhibitor that reduces the synthesis of glucosylceramide. Preliminary results in phase II clinical trials show the oral therapy to positively affect neurological features in adults with type 3 Gaucher disease.

Click here for Phase II publication Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial – PubMed (nih.gov)

Click here for Phase III study information.

Click here for an IGA information webinar on the current phase III LEAP2MONO clinical study.

Clinical study in GD 1 and 3

Paediatric patients needed for a clinical research study testing an orally administered treatment in Gaucher disease types 1 & 3

This study will investigate if the investigational treatment, a substrate reduction therapy, works and its safety profile in paediatric patients with Gaucher disease type 1 & 3. Patients participating in the study will receive, based on their disease symptoms, either the study drug alone (cohort 1) or in combination with a currently approved enzyme replacement therapy (cohort 2). Patients may receive the study drug for up to 24 months. The safety of the study drug will be assessed through clinical lab evaluations, cardiological exams, hearing as well as neuropsychological tests. Efficacy will be evaluated through abdominal and bone images, and Gaucher Disease assessments.

Sixty patients will participate in this study that is currently conducted in multiple countries including Russia, Turkey, Canada, Argentina, Italy, Sweden, France, Spain, the United Kingdom, and Japan.

To participate in the study, patients should meet at least the following study criteria:

  • be less than 18 years old
  • have Gaucher disease type 1 or 3
  • have received treatment with enzyme replacement therapy for at least 2 years and meet study specified Gaucher Disease treatment goals (cohort 1) or have severe clinical manifestation of Gaucher Disease despite receiving adequate treatment with enzyme replacement therapy for at least 3 years, being at a stable dose for the past 6 months (cohort 2).

If you are interested in more information, contact your treating physician who could assess your eligibility for the study.

Further information can be obtained on www.clinicaltrials.gov, using study identifier NCT 03485677, or at www.clinicaltrialsregister.eu using study number EudraCT 2016-000301-37

Prenatal Enzyme Replacement for Gaucher disease type 2 and type 3

The University of California, San Francisco (UCSF) is enrolling participants in an FDA-approved clinical trial of prenatal enzyme replacement therapy (ERT) for neuronopathic Gaucher disease types 2 and 3. Treating these conditions before birth may improve survival rates and outcomes for infants. The Prenatal Enzyme Replacement for Lysosomal Storage Diseases—UCSF Pearl Trial —is open to pregnant patients worldwide, and travel support is provided.

Visit PearlTrial.ucsf.edu for more information. Contact the study team directly by completing a questionnaire, by email fetaltreatmentcenter@ucsf.edu, or #1-800-RX-FETUS. (ClinicalTrials.gov/study/NCT04532047).

Individuals with Gaucher (types 2 and 3) can contribute by participating in the International Registry of Patients Diagnosed with Lysosomal Storage Diseases.

Last updated 19 August 2024

Closed clinical trials.

× How can I help you?